Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 4/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147523 | 0.91 | GAA (0.43) | KDM4EL3MBTL1TDP1STING1DRD2 | |
| SCHEMBL12888449 | 0.89 | KDM4E (0.44) | KDM4EL3MBTL1TDP1STING1TLR7 | |
| SCHEMBL3353897 | 0.87 | TLR7 (0.47) | KDM4EL3MBTL1TDP1STING1TLR7 | |
| SCHEMBL1231989 | 0.86 | KDM4E (0.45) | KDM4EL3MBTL1TDP1STING1DRD2 | |
| SCHEMBL4309229 | 0.86 | STING1 (0.46) | KDM4EL3MBTL1TDP1STING1DRD2 | |
| SCHEMBL4157089 | 0.85 | TLR7 (0.49) | KDM4EL3MBTL1TDP1STING1DRD2 | |
| SCHEMBL5124567 | 0.85 | STING1 (0.46) | KDM4EL3MBTL1TDP1STING1DRD2 | |
| SCHEMBL5129239 | 0.84 | STING1 (0.46) | KDM4EL3MBTL1TDP1STING1DRD2 | |
| SCHEMBL202268 | 0.84 | KDM4E (0.41) | KDM4EL3MBTL1TDP1STING1DRD2 | |
| SCHEMBL202649 | 0.84 | KDM4E (0.41) | KDM4EL3MBTL1TDP1STING1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8343993-B2 | Hydroxyalkyl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20090253695-A1 | Hydroxyalkyl Substituted Imidazonaphthyridines | COLEY PHARMACEUTICAL GROUP, INC, (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | KDM4E 2956/4885L3MBTL1 2979/4885TDP1 3223/4885 |
| US-20090253695-A1 | Hydroxyalkyl Substituted Imidazonaphthyridines | IFNG, IFNAR1, IRF3 | KDM4E 3153/4885L3MBTL1 2355/4885TDP1 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.